Dr. Glenn Chertow is a preeminent nephrologist and academic leader who serves as the Norman S. Coplon/Satellite Healthcare Professor of Medicine and Chief of the Division of Nephrology at Stanford University School of Medicine. He received his medical degree from Harvard Medical School and a Master of Public Health from the Harvard School of Public Health, followed by internal medicine residency and nephrology fellowship training at Brigham and Women's Hospital in Boston. Before joining Stanford in 2007, Dr. Chertow established his academic career at Harvard Medical School and Brigham and Women's Hospital from 1995 to 1998, then at the University of California San Francisco from 1998 to 2007. Throughout his distinguished career, he has built a reputation for excellence in clinical research, education, and patient care in the field of kidney disease. His leadership has been instrumental in advancing the Division of Nephrology at Stanford into one of the nation's premier centers for kidney research and clinical care.
Dr. Chertow's research program has profoundly influenced the field of nephrology through rigorous clinical epidemiology, health services research, and large-scale clinical trials that have directly impacted patient care standards worldwide. He has served as principal investigator or key leader for numerous landmark studies including the Mortality and Morbidity in Hemodialysis Study, the Acute Renal Failure Trials Network, the Frequent Hemodialysis Network, and the Systolic Blood Pressure Intervention Trial, which have redefined treatment approaches for patients with kidney disease. His scholarly work has established new methodological standards for evaluating outcomes in dialysis patients and has provided critical evidence for healthcare policy decisions affecting millions of individuals with kidney disorders. With hundreds of peer-reviewed publications, Dr. Chertow has shaped contemporary understanding of acute kidney injury, chronic kidney disease, and end-stage renal disease through meticulous scientific inquiry. His contributions have earned him recognition as one of the most influential researchers in modern nephrology, with work that continues to set the agenda for clinical practice and research.
As an educator and mentor, Dr. Chertow has dedicated significant effort to cultivating the next generation of nephrology researchers and clinicians, guiding numerous fellows and junior faculty members who have gone on to establish successful careers in academic medicine. He maintains active leadership in cutting-edge clinical research, including his current work on neutrophil and monocyte deactivation in acute kidney injury, demonstrating his ongoing commitment to translating scientific discoveries into clinical applications. Holding courtesy appointments in Epidemiology and Population Health and Health Policy, Dr. Chertow fosters interdisciplinary collaborations that extend the impact of nephrology research beyond traditional boundaries. His service on data safety monitoring boards for industry-sponsored trials and advisory roles for major clinical studies underscores his standing as a respected authority in the design and implementation of rigorous clinical research. Dr. Chertow continues to shape the future of kidney disease management through his visionary leadership, ensuring that scientific advances translate into meaningful improvements in patient outcomes worldwide.
